原始来源记录
决策级顶线结果
ADCT：LOTIS-5 III期主要终点PFS达到ZYNLONTA联合利妥昔单抗的顶线数据
LOTIS-5 III期试验以统计学意义达到主要PFS终点（HR 0.73，p=0.008）。ADC Therapeutics计划于2026年8月与FDA召开sBLA前会议，并于2026年第四季度提交sBLA，以寻求ZYNLONTA联合利妥昔单抗用于复发/难治性DLBCL的完全批准。
关键事实
- 申报时间
- 2026年6月3日 20:17
- 事件
- 顶线结果
- 方向
- 积极
- 来源
- SEC 8-K
- 可信度
- 有来源
- HR
- 0.73
- CR rate
- 39.5% vs 26.7%
- p-value
- 0.008
- median PFS
- 6.1 vs 4.7 months
- median docr
- 16.8 vs 12.3 months
来源摘录
false 0001771910 0001771910 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2026 ADC Therapeutics SA (Exact Name of Registrant as Specified in Its Charter) Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N/A (IRS Employer Identification Number) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code) + 41 21 653 02 00 (Registrant’s Telephone Number) N/A (Former Name or Former Address, if Changed Since Last Report) Ch